These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 26976923)
1. Response to Letter Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation". Schmidt C; Wiedmann F; Voigt N; Zhou XB; Heijman J; Lang S; Albert V; Kallenberger S; Ruhparwar A; Szabó G; Kallenbach K; Karck M; Borggrefe M; Biliczki P; Ehrlich JR; Baczkó I; Lugenbiel P; Schweizer PA; Donner BC; Katus HA; Dobrev D; Thomas D Circulation; 2016 Mar; 133(11):e440-1. PubMed ID: 26976923 [No Abstract] [Full Text] [Related]
2. Letter by Olschewski et al Regarding Article, "Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation". Olschewski A; Chandran N; Olschewski H Circulation; 2016 Mar; 133(11):e439. PubMed ID: 26976922 [No Abstract] [Full Text] [Related]
3. Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation. Schmidt C; Wiedmann F; Voigt N; Zhou XB; Heijman J; Lang S; Albert V; Kallenberger S; Ruhparwar A; Szabó G; Kallenbach K; Karck M; Borggrefe M; Biliczki P; Ehrlich JR; Baczkó I; Lugenbiel P; Schweizer PA; Donner BC; Katus HA; Dobrev D; Thomas D Circulation; 2015 Jul; 132(2):82-92. PubMed ID: 25951834 [TBL] [Abstract][Full Text] [Related]
4. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773 [TBL] [Abstract][Full Text] [Related]
5. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept. Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994 [TBL] [Abstract][Full Text] [Related]
7. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis. Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141 [TBL] [Abstract][Full Text] [Related]